GlassScriptPhysician profile
Arturo Olivera
NPI 1922097831
$9,717.45
in general payments reported to CMS, 2019-2025
33 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $237 · 2021: $873 · 2022: $1,506 · 2023: $2,355 · 2024: $1,847 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,779 · Education: $73.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,779.39 |
| Education | $73.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,301.13 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,008.34 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $984.32 | 2019-2025 | Entyvio |
| Pfizer INC. | $848.49 | 2019-2025 | |
| Janssen Biotech, INC. | $541.34 | 2019-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $379.41 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $378.00 | 2019-2025 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $329.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $297.46 | 2021-2024 | Zeposia |
| Genzyme Corporation | $270.07 | 2023-2025 | |
| Allergan, INC. | $265.96 | 2019 | |
| Ironwood Pharmaceuticals, INC | $206.92 | 2019-2024 | Linzess |
| Novo Nordisk INC | $194.84 | 2022-2025 | Wegovy |
| Boston Scientific Corporation | $183.95 | 2019-2023 | Orcapod |
| Phathom Pharmaceuticals, INC. | $178.80 | 2024-2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $163.49 | 2019 | |
| Merck Sharp & Dohme LLC | $149.73 | 2019-2024 | Dificid |
| Gilead Sciences, INC. | $132.01 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.32 | 2023-2024 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $125.05 | 2024-2025 | Iqirvo, Bylvay |
| Regeneron Healthcare Solutions, INC. | $118.32 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $108.02 | 2019-2025 | |
| Mauna Kea Technologies, INC. | $92.18 | 2019 | |
| Laborie Medical Technologies Corp. | $72.93 | 2024 | |
| Celltrion USA INC. | $45.16 | 2024 | Vegzelma, Zymfentra |
| Echosens North America, INC. | $36.86 | 2023-2025 | Fibroscan, Fibroscan |
| Cook Medical LLC | $32.61 | 2023 | Hemospray |
| Redhill Biopharma INC. | $31.06 | 2020-2021 | |
| Lucid Diagnostics INC. | $28.01 | 2023 | |
| Romark Laboratories, Lc | $27.86 | 2019 | |
| Amag Pharmaceuticals, INC. | $23.31 | 2022 | |
| Qol Medical, LLC | $21.19 | 2022 | |
| Exact Sciences Corporation | $15.90 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arturo Olivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.